Hjem › Sigdcelleanemi › New York
Kliniske studier for Sigdcelleanemi i New York
21 studier for Sigdcelleanemi søker deltakere på steder i New York.
Byer i New York
Offisiell studietekst (engelsk)
A Study to Investigate the Efficacy and Safety of Crizanlizumab (5 mg/kg) Compared With Placebo in Adolescent and Adult Sickle Cell Disease Patients Who Experience Frequent Vaso-Occlusive Crises (SPARKLE)
- Childrens Hospital at Montefiore, The Bronx
RekruttererFase 3
Alder 12 til 100 · Alle kjønn · Oppdatert 28. sep. 2026 · NCT06439082A Phase 1b, Open-Label Study of DISC-3405 in Participants With Sickle Cell Disease (SCD)
- Mount Sinai Hospital, New York
RekruttererFase 1
Alder 18 og eldre · Alle kjønn · Oppdatert 23. sep. 2026 · NCT07187973A Research Study Looking at Long-term Treatment With Etavopivat in People With Sickle Cell Disease or Thalassaemia
- Columbia University Medical Center_New York_0, New York
- Columbia University Medical Center_New York_0, New York
RekruttererFase 3
Alder 2 og eldre · Alle kjønn · Oppdatert 18. sep. 2026 · NCT06609226A Study to Evaluate How Well Etavopivat Works in People With Sickle Cell Disease
- NYC Health+Hospitals, Brooklyn
- Interfaith Medical Center, Brooklyn
- Cohen Children's Medical Ctr, Queens
- og 2 flere
RekruttererFase 3
Alder 12 og eldre · Alle kjønn · Oppdatert 17. sep. 2026 · NCT06612268A Phase 2/3 Study of Osivelotor in Adult and Adolescent Participants With SCD
- Icahn School of Medicine at Mount Sinai, New York
- Jacobi Medical Center, The Bronx
RekruttererFase 2/3
Alder 12 og eldre · Alle kjønn · Oppdatert 18. aug. 2026 · NCT05431088ATHN Transcends: A Natural History Study of Non-Neoplastic Hematologic Disorders
- Western New York BloodCare, Buffalo
- Northwell Health Hemostasis and Thrombosis Center at Long Island Jewish and Cohen Children's Medical Center, Hyde Park
- Weill Cornell Medical College - New York Presbyterian Hospital, New York
- og 2 flere
RekruttererObservasjonsstudie
Alle aldre · Alle kjønn · Oppdatert 17. aug. 2026 · NCT04398628Safety, Efficacy, and Pharmacokinetics of CSL889 in Adults and Adolescents With Sickle Cell Disease During Vaso-Occlusive Crisis
- Mount Sinai Medical Center, New York
- Jacobi Medical Center, The Bronx
RekruttererFase 2
Alder 12 og eldre · Alle kjønn · Oppdatert 14. aug. 2026 · NCT06699849Safety of Anumigilimab (CSL324) in Adults With Sickle Cell Disease (SCD)
- Jacobi Medical Center, The Bronx
RekruttererFase 2
Alder 18 og eldre · Alle kjønn · Oppdatert 5. aug. 2026 · NCT07224360The Efficacy and Safety of Rilzabrutinib in Participants Aged 10 to 65 Years With Sickle-cell Disease
- Richmond University Medical Center- Site Number : 8400038, Staten Island
- Montefiore Medical Center - Moses Campus- Site Number : 8400057, The Bronx
RekruttererFase 3
Alder 10 til 65 · Alle kjønn · Oppdatert 29. jul. 2026 · NCT06975865Myeloablative Conditioning, Prophylactic Defibrotide and Haplo AlloSCT for Patients With Sickle Cell Disease
- New York Medical College, Valhalla
RekruttererFase 2
6 Months – 21 Years · Alle kjønn · Oppdatert 27. jul. 2026 · NCT02675959Gene Correction in Autologous CD34+ Hematopoietic Stem Cells (HbS to HbA) to Treat Severe Sickle Cell Disease
- Columbia University Irving Medical Center, New York
- Memorial Sloan Kettering, New York
RekruttererFase 1/2
Alder 12 til 50 · Alle kjønn · Oppdatert 2. jul. 2026 · NCT04819841131I-apamistamab-based Conditioning for Hematopoietic Stem Cell Transplant (HSCT) in Advanced Sickle Cell Disease (SCD)
- Columbia University Irving Medical Center, New York
RekruttererFase 1
Alder 12 til 50 · Alle kjønn · Oppdatert 10. jun. 2026 · NCT07015684Comparing the Effectiveness of Matched Related Donor Hematopoietic Stem Cell Transplantation to Disease Modifying Therapy in Pediatric Patients With Sickle Cell Disease
- Roswell Park (MRD-HCT), Buffalo
- Columbia Presbytarian (NT-DMT), New York
- Cohen's Children Hospital (NT-DMT), Queens
- og 4 flere
RekruttererObservasjonsstudie
Alder 3 til 20 · Alle kjønn · Oppdatert 4. jun. 2026 · NCT06941389A Study of Immune Suppression Treatment for People With Sickle Cell Disease or β-Thalassemia Who Are Going to Receive an Allogeneic Hematopoietic Cell Transplantation (HCT)
- Memorial Sloan Kettering Suffolk - Commack (Consent only), Commack
- Memorial Sloan Kettering Westchester (Consent only), Harrison
- Memorial Sloan Kettering Nassau (All protocol activities), Rockville Centre
RekruttererFase 2
Alder 2 til 50 · Alle kjønn · Oppdatert 3. jun. 2026 · NCT05736419Evaluation of Efficacy and Safety of a Single Dose of CTX001 in Participants With Transfusion-Dependent β-Thalassemia and Severe Sickle Cell Disease
- New York Presbyterian Hospital - Morgan Stanley Children's Hospital, New York
RekruttererFase 3
Alder 12 til 35 · Alle kjønn · Oppdatert 23. mar. 2026 · NCT05477563Minimizing Toxicity in HLA-identical Sibling Donor Transplantation for Children With Sickle Cell Disease
- Columbia University, New York
RekruttererFase 2
Alder 2 til 25 · Alle kjønn · Oppdatert 10. mar. 2026 · NCT03587272A Long-term Follow-up Study in Patients Who Received BEAM-101
- Columbia University Irving Medical Center, New York
RekruttererObservasjonsstudie
Alder 14 til 37 · Alle kjønn · Oppdatert 28. jan. 2026 · NCT07373639Peer Support for Adolescents and Emerging Adults With Sickle Cell Pain
- Weil Cornell Medical College, New York
- University of Rochester Medical Center, Rochester
Rekrutterer
Alder 16 til 30 · Alle kjønn · Oppdatert 7. jan. 2026 · NCT06374238Cannabinoids for the Reduction of Inflammation and Sickle Cell Related Pain
- Mount Sinai Hospital, New York
RekruttererFase 2
Alder 18 og eldre · Alle kjønn · Oppdatert 2. okt. 2025 · NCT05519111AlloSCT for Malignant and Non-malignant Hematologic Diseases Utilizing Alpha/Beta T Cell and CD19+ B Cell Depletion
- New York Medical College, Valhalla
RekruttererFase 2
1 Day – 30 Years · Alle kjønn · Oppdatert 8. aug. 2025 · NCT04099966Cannabidiol in Sickle Cell Disease
- Icahn School of Medicine at Mount Sinai, Manhattan
RekruttererFase 1/2
Alder 18 og eldre · Alle kjønn · Oppdatert 25. jun. 2025 · NCT06930703Fra ClinicalTrials.gov, data hentet 5. okt. 2026. Hver studie setter sine egne kvalifikasjonskrav; studieteamet avgjør hvem som kan delta.